Mortality in systemic lupus erythematosus: causes, predictors and interventions
- PMID: 30338717
- DOI: 10.1080/1744666X.2018.1538789
Mortality in systemic lupus erythematosus: causes, predictors and interventions
Abstract
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by organ damage, flare-remission pattern, and increased mortality when compared with the general population. SLE mortality depends on epidemiological, sociodemographic, genetic, and clinical factors. Mortality causes have been mainly grouped in disease activity, infections, and cardiovascular complications. Lupus nephritis and neuropsychiatric lupus are the main manifestations associated to mortality. Bacterial infection remains an important cause of death, and cardiovascular mortality is almost double when compared to age - and sex-matched comparisons. Characteristics such as time from onset to diagnosis > 1-year, renal involvement, high SLEDAI and severe organ involvement, may be predictors of mortality. Interventions including steroids, immunosuppressants, plasmapheresis, some biologics, and vaccination have shown efficacy in reducing mortality rates. Areas covered: In this narrative review the epidemiology, main causes of mortality, potential predictors, and interventions are described. Expert commentary: Despite early diagnosis and immunosuppressive treatment, SLE mortality remains high. African-American, Hispanic-American origin, low socioeconomic status and male sex are associated with increased mortality. Currently, there is no unique, precise prediction model for mortality; however, predictors for increased activity such as infections and cardiovascular events, lead to increased mortality. New prediction models may indicate early interventions in order to improve mortality rates.
Keywords: SLE; cardiovascular events; causes; flares; infections; lupus nephritis; mortality; predictors; standardized mortality ratio.
Similar articles
-
Systemic lupus erythematosus in three ethnic groups. VII [correction of VIII]. Predictors of early mortality in the LUMINA cohort. LUMINA Study Group.Arthritis Rheum. 2001 Apr;45(2):191-202. doi: 10.1002/1529-0131(200104)45:2<191::AID-ANR173>3.0.CO;2-2. Arthritis Rheum. 2001. PMID: 11324784
-
Mortality Among Hospitalized Individuals With Systemic Lupus Erythematosus in the US Between 2006 and 2016.Arthritis Care Res (Hoboken). 2021 Oct;73(10):1444-1450. doi: 10.1002/acr.24356. Epub 2021 Aug 31. Arthritis Care Res (Hoboken). 2021. PMID: 32558160 Free PMC article.
-
A multiethnic, multicenter cohort of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE.Arthritis Rheum. 2007 May 15;57(4):576-84. doi: 10.1002/art.22672. Arthritis Rheum. 2007. PMID: 17471524
-
An update on mortality in systemic lupus erythematosus.Clin Exp Rheumatol. 2008 Sep-Oct;26(5 Suppl 51):S72-9. Clin Exp Rheumatol. 2008. PMID: 19026147 Review.
-
Epidemiology of systemic lupus erythematosus.Expert Rev Clin Immunol. 2017 Aug;13(8):799-814. doi: 10.1080/1744666X.2017.1327352. Epub 2017 May 16. Expert Rev Clin Immunol. 2017. PMID: 28471259 Review.
Cited by
-
Unfavorable Outcomes Associated With Glucocorticoid Use in Current Standard-of-Care Management of Systemic Lupus Erythematosus in Canada.ACR Open Rheumatol. 2024 Sep;6(9):531-539. doi: 10.1002/acr2.11680. Epub 2024 Jun 25. ACR Open Rheumatol. 2024. PMID: 38924684 Free PMC article.
-
Lupus serum IgG induces microglia activation through Fc fragment dependent way and modulated by B-cell activating factor.J Transl Med. 2019 Dec 21;17(1):426. doi: 10.1186/s12967-019-02175-0. J Transl Med. 2019. PMID: 31864410 Free PMC article.
-
Association of primary Sjögren's syndrome with incident heart failure: a secondary analysis of health claims data in Taiwan.Ther Adv Chronic Dis. 2022 Feb 22;13:20406223221078083. doi: 10.1177/20406223221078083. eCollection 2022. Ther Adv Chronic Dis. 2022. PMID: 35222904 Free PMC article.
-
The Role of Heme Oxygenase-1 as an Immunomodulator in Kidney Disease.Antioxidants (Basel). 2022 Dec 13;11(12):2454. doi: 10.3390/antiox11122454. Antioxidants (Basel). 2022. PMID: 36552662 Free PMC article. Review.
-
Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression.Ann Rheum Dis. 2024 Mar 12;83(4):464-474. doi: 10.1136/ard-2023-224919. Ann Rheum Dis. 2024. PMID: 38233103 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical